Table 5.

Induction outcome by Pgp expression and treatment arm

AraC-DNR
(N = 59)
AraC-DNR
(N = 31)
AraC-DNR + CsA
(N = 70)
AraC-DNR + CsA
(N = 37)
No. of
patients
Percent of
patients (CI)
No. of
patients
Percent of
patients (CI)
No. of
patients
Percent of
patients (CI)
No. of
patients
Percent of
patients (CI)
Pgp (D < 0.20) patients only         
 CR 20 34  (22-47)   27 39  (27-51)   
 RD 29 49  (36-63)   25 36  (25-48)   
 Died during aplasia     
 Indeterminate5-150 10   12 17   
 Not adequately assessed     
Pgp+ (D ≥ 0.20) patients only         
 CR   26  (12-45)   17 46  (29-63) 
 RD   14 45  (27-64)   11 30  (16-47) 
 Died during aplasia     
 Indeterminate5-150   26   11 
 Not adequately assessed     
AraC-DNR
(N = 59)
AraC-DNR
(N = 31)
AraC-DNR + CsA
(N = 70)
AraC-DNR + CsA
(N = 37)
No. of
patients
Percent of
patients (CI)
No. of
patients
Percent of
patients (CI)
No. of
patients
Percent of
patients (CI)
No. of
patients
Percent of
patients (CI)
Pgp (D < 0.20) patients only         
 CR 20 34  (22-47)   27 39  (27-51)   
 RD 29 49  (36-63)   25 36  (25-48)   
 Died during aplasia     
 Indeterminate5-150 10   12 17   
 Not adequately assessed     
Pgp+ (D ≥ 0.20) patients only         
 CR   26  (12-45)   17 46  (29-63) 
 RD   14 45  (27-64)   11 30  (16-47) 
 Died during aplasia     
 Indeterminate5-150   26   11 
 Not adequately assessed     
F5-150

Died within 7 days after completing induction therapy; or died later with (1) no posttreatment marrow examination and (2) no posttreatment peripheral blood smear demonstrating leukemia.

or Create an Account

Close Modal
Close Modal